VCAM-1 antagonists proved superior to ICAM-1 and MAdCAM-1 blockade in the murine model of DSS colitis (23), and the monoclonal anti-α4 integrin antibody natalizumab has been successfully used for blockade of VCAM-1-dependent leukocyte trafficking in patients with active CD (24–27). The gene discussed is ICAM1; the disease is colitis.